

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date:

4/16/99

By:



Charles K. Sholtz

14

#74/  
IDS

DOCKET No. 07953.0004.999

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Pamela R. CONTAG

SERIAL NO.: 08/844,336

FILED: April 18, 1997

FOR: **BIODETECTORS TARGETED  
TO SPECIFIC LIGANDS**

EXAMINER: V. Ryan

ART UNIT: 1641

**FILE COPY**

### FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on the accompanying Form-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56 1.97 and 1.98.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$240.00). Attached is a check which includes the amount of \$ 240.00. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0652. A duplicate copy of this communication is enclosed.

**BEST AVAILABLE COPY**

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date:

April 15, 1999



Charles K. Sholtz  
Reg. No. 38,615

**Correspondence Address:**

Howry & Simon  
301 Ravenswood Avenue  
Menlo Park, CA 94025  
(650) 463-8100

BEST AVAILABLE COPY

[illegible]

BEST AVAILABLE COPY

TO THE  
ORDER  
OF

Commissioner of Patents &amp; Trademarks

PAY  
Two Hundred Forty

## XENOGEN CORPORATION

880 ATLANTIC AVENUE  
ALAMEDA, CA 94501BANK OF AMERICA  
SAN JOSE MAIN BRANCH  
101 PARK CENTER PLAZA  
SAN JOSE, CA 95128  
11-35-1210

CHECK NO.

2073

2073

DATE  
4/1/99AMOUNT  
\$240.00

⑈002073⑈ ⑆121000358⑆ 00351⑈18225⑈

Security features included. Details on back.

Date: April 16, 1999

Date: April 16, 1999

Attorney Docket No.: PXE-002-SN, 07953, 0004, 959  
OKS 4/16/99

Applicant:

Pamela R. Contag, et al.

Application Serial Number:

08/844,336


Application Filing Date:

April 18, 1997

Title: **Biodetectors Targeted to Specific Ligands.**

Paper(s) enclosed:

- 4<sup>th</sup> Supplemental Information Disclosure Statement
- PTO Form 1449 7 OKS 4/16/99
- Copies of 8 cited references
- Check # ~~548~~ in the amount of \$240.00
- Return Post Card 2073 OKS 4/16/99



RECEIVED BY THE U.S. PATENT AND TRADEMARK OFFICE

BEST AVAILABLE COPY